Previous 10 | Next 10 |
Orchard Therapeutics ( ORTX ) is an undercovered, $1.7bn London-headquartered company positioning itself to be the market leader in next-generation, cryopreserved, easily accessible, lentiviral vector based gene therapy. The company originally had 2 gene therapy assets. In 2018, Orchard Therap...
Orchard Therapeutics plc (ORTX) Q1 2020 Earnings Conference Call May 07, 2020 8:00 AM ET Company Participants Renee Leck – Director-Investor Relations Bobby Gaspar – Chief Executive Officer Frank Thomas – Chief Operating Officer Conference Call Participant...
The following slide deck was published by Orchard Therapeutics plc in conjunction with their 2020 Q1 earnings Read more ...
Portfolio Investments More Tightly Prioritized Around High Need, High Value Indications First Disease Targets Extending Platform into Less Rare Indications Disclosed Updated Timelines Provided for MLD and MPS-I Programs California Facility Investment Terminated with Near-ter...
Most doctors are prisoners of their education and shackled by their profession. ” - Richard Diaz A month ago we offered up the analysis below on this 'watch item' biotech stock from across the pond exclusively to Biotech Forum members. The stock is up over 40% since then but the ...
BOSTON and LONDON, May 01, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will host a conference call and live webcast on Thursday, May 7, 2020, at 8:00 a.m. ET to report its first quarter 2020 financial results a...
Most Comprehensive Presentation of Orchard Clinical Data to Date; Spans Five Disease Areas and Highlights Broad Applicability of Hematopoietic Stem Cell Gene Therapy Approach Accepted Abstracts Include Data on Investigational Gene Therapies for Neurometabolic Conditions, Including Upd...
BOSTON and LONDON, April 27, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the first patient has been dosed in an open-label, proof-of-concept investigational study of OTL-201, an ex vivo autologous hema...
Matinas BioPharma Slumps After Amarin Case Verdict Matinas BioPharma ( MTNB ) stock slumped after a US District Court decided to invalidate Amarin Corporation's (AMRN) Vascepa. While the verdict is ostensibly in favor of generic drugs, Matinas stock reacted negatively to the news. Howeve...
Citing the impact from the COVID-19 pandemic, Orchard Therapeutics (NASDAQ: ORTX ) updates on its pipeline: More news on: Orchard Therapeutics plc, Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Orchard Therapeutics plc Company Name:
ORTX Stock Symbol:
NASDAQ Market:
Orchard Therapeutics plc Website:
TOKYO, LONDON and BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe, today announced that Bobby Gaspar, M.D., Ph.D., co-founder and chief executive officer, ...
Crescent Energy Company Class A (CRGY) is expected to report $0.21 for Q4 2023 ThredUp Inc. (TDUP) is expected to report $-0.13 for Q4 2023 Wright Investors` Service Holdings Inc (IWSH) is expected to report for Q4 2023 Bridgford Foods Corporation (BRID) is expected to report for Q1 2...
Gene therapy being developed as a one-time treatment to address the underlying cause of the disease by inserting a functional copy of the human IDUA gene into a patient’s own hematopoietic stem cells HURCULES study to enroll 40 patients at clinical sites across the U.S....